©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Identification of the Second Membrane-type Matrix Metalloproteinase (MT-MMP-2) Gene from a Human Placenta cDNA Library
MT-MMPs FORM A UNIQUE MEMBRANE-TYPE SUBCLASS IN THE MMP FAMILY (*)

(Received for publication, June 8, 1995; and in revised form, July 10, 1995)

Takahisa Takino (1)(§) Hiroshi Sato (1) Akira Shinagawa (2) Motoharu Seiki (1)(¶)

From the  (1)Department of Molecular Virology and Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920, Japan and the (2)Department of Biochemistry, Research Institute, Fuji Chemical Industries Limited, Takaoka, Toyama 933, Japan

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Membrane-type matrix metalloproteinase (MT-MMP), which we have identified recently, is unique in its transmembrane (TM) domain at the C terminus and mediates activation of pro-gelatinase A on the cell surface (Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65; [Medline] Takino, T., Sato, H., Yamamoto, E., and Seiki, M.(1995) Gene (Amst.) 115, 293-298). In addition to MT-MMP, a novel MMP-related cDNA of 2.1 kilobases was isolated from a human placenta cDNA library. The cDNA contains an open reading frame for a new MMP. The deduced protein composed of 604 amino acids was closely related to MT-MMP in the amino acid sequence (66% homology at the catalytic domains) and has a potential TM domain at the C terminus. Monoclonal antibodies raised against the synthetic peptide recognized a 64-kDa protein as the major product in the transfected cells. TIMP-1 fused with the potential TM domain was localized on the cell surface while native TIMP-1 is in the culture medium. Thus, we called the second membrane-type MMP, MT-MMP-2 and renamed MT-MMP, MT-MMP-1. MT-MMP-1 and -2 are thought to form a distinct membrane-type subclass in the MMP family since all the others are secreted as soluble forms. Like MT-MMP-1, expression of MT-MMP-2 induced processing of pro-gelatinase A (68-kDa in gelatin zymography) into the activated form of 62-kDa fragments through a 64-kDa intermediate form. Expression of MT-MMP-2 mRNA was at the highest levels in the brain where MT-MMP-1 was at the lowest level compared to other tissues. MT-MMP-1 and -2 are thought to be utilized for extracellular matrix turnover on the surface of cells under different genetic controls.


INTRODUCTION

Matrix metalloproteinases (MMPs) (^1)are a family of enzymes that share a common domain structure composed of propeptide, catalytic, hinge, and hemopexin-like domains (exception is MMP-7bulletmatrilysin, which lacks a hemopexin-like domain)(3, 4) . These enzymes are responsible for the turnover of extracellular matrix by degrading native macromolecules, including a variety of collagens and glycoproteins such as fibronectin and laminin, and play crucial roles in tissue remodeling during morphogenesis, wound healing, angiogenesis, and also in many pathological conditions such as tumor invasion and rheumatoid arthritis(5, 6, 7, 8, 9, 10) . 11 MMPs encoded by different genes are known as the MMP family members, and they have different substrate specificity against extracellular matrix macromolecules. 10 of them are produced by cells as a soluble zymogen form, but the last one, which we recently discovered, has a transmembrane domain at the C terminus and is expressed as a membrane protein(1, 2, 11) . Thus, we called this ectoenzyme membrane-type MMP (MT-MMP).

All of the MMPs are expressed as inactive zymogens and need proteolytic activation for them to function. Although serine proteases such as plasmin, neutrophil elastase, and trypsin can activate several MMP zymogens in a test tube(12, 13) , little is known about the activators in tissue. MMP-2bulletgelatinase A cannot be activated by these serine proteinases (14, 15) but is activated on the surfaces of fibroblasts (16) and tumor cell lines treated with 12-O-tetradecanoylphorbol-13-acetate or concanavalin A (17, 18, 19) . Thus, a unique activator on the cell surface was expected to be responsible for gelatinase A activation, and it turned out to be MT-MMP. Expression of MT-MMP in the transfected cells induced specific activation of gelatinase A in a cell-mediated manner(1) . Appearance of the activated form of gelatinase A in the tissue is also a characteristic feature of invasive carcinomas(20, 21) . Expression of MT-MMP was detected there, and the product was immunolocalized in and on the carcinoma cells(1) . Since gelatinase A is an important enzyme for basement membrane invasion by degrading type IV collagen, MT-MMP on the tumor cell surface is thought to play a critical role in the invasive phenotype of tumor cells.

MT-MMP cDNA was isolated from a human placenta cDNA library using a MMP-related gene fragment as a probe(2) . The probe with a possible new MMP gene sequence was obtained from the amplified cDNA fragments by polymerase chain reaction (PCR) using degenerate oligonucleotide primers corresponding to the conserved sequences within the MMP family. The structural characteristic of MT-MMP is the transmembrane domain at the C terminus and two more additional insertions. One is the insertion of 8 amino acids in the catalytic domain, and the other is the insertion of 11 amino acids between the propeptide and the catalytic domain. MMP-11bulletstromelysin-3 (22) has a similar insertion of 10 amino acids between propeptide and catalytic domain, and RXKR sequences, potential recognition sites for subtilisin-like processing enzymes(23) , are conserved between them. No insertion corresponding to the 8 amino acids of MT-MMP was found in the other members of the MMP family.

Both MT-MMP and stromelysin-3 were identified by cDNA cloning instead of the conventional biochemical purification of the enzymes. Thus, new MMP members may be obtained further by survey of the MMP-related genes. To identify yet unknown MMP members, we extended our previous study to survey the MMP-related cDNAs amplified from various human tissues by reverse transcription-PCR. In this study, we identified a fragment of another new MMP-related gene from a human melanoma tissue. This fragment was used as a probe to screen a human placenta cDNA library, and a cDNA fragment that encodes a new MMP having a TM domain at the C terminus was obtained. Thus, MT-MMPs form a distinct subgroup in the MMP family.


MATERIALS AND METHODS

Amplification of MMP cDNA Fragments and Molecular Cloning

Amplification of the MMP cDNA fragment was carried out as reported(2) . Briefly, mRNA samples extracted from various sources were reverse transcribed with SuperScript reverse transcriptase (Life Technologies, Inc.) using random hexamers as primers. Aliquots of the reaction mixture were amplified using Taq polymerase with 30 rounds of PCR. Primers (5P-4 and 3P-2) were the previously reported degenerate oligonucleotides designed from the conserved amino acid sequence SGNVVNGCWGAYATMRTSAT and 3P-2 to YTCRTSNTCRTCRAARTGRRHRTCYCC in the catalytic enzyme domain. The PCR products (120-130 base pairs) were separated in a 10% polyacrylamide gel electrophoresis and subcloned into a plasmid. The nucleotide sequences of the inserts were determined using an automated sequencer (Applied Biosystems model 373A DNA sequenator). A possible new MMP gene deduced from one of the amplified cDNA fragment was tentatively designated as MMP-X2.

A human placenta cDNA library (Clontech), which was constructed using oligo(dT)- and random-primed cDNA was screened with the MMP-X2 cDNA fragment as a probe.

Construction of the Expression Plasmids

A eukaryotic expression vector pSG5 (Stratagene) that has a simian virus 40 early promoter was used to express the proteins and chimeric proteins in the transfected cells. Chimeric proteins between TIMP-1 (24) and the TM domains of MT-MMP-1 (TIMP/MT-1) (11) or MT-MMP-2 (TIMP/MT-2) were constructed as follows. cDNA fragments encoding the C terminus of MT-MMP-1 (Gly to Val) containing the deduced TM domain (Ala to Phe) or the C terminus of MT-MMP-2 (Ala to Val) containing the deduced TM domain (Val to Phe) were amplified by PCR. The amplified products were joined to the 3`-end of the TIMP-1 cDNA fragment to express both proteins as fusion proteins.

Cell Culture and Transfection

Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal calf serum and 2 mM glutamate under a 5% CO(2) atmosphere. Cells were transfected with plasmids by the calcium phosphate method as described(9, 25) .

Monoclonal Antibodies

A peptide corresponding to a unique insertion of MT-MMP-2, FEEVPYSELENGKRD(167-181), was synthesized and used for immunization of a mouse. Monoclonal antibodies were 50-1H7 for TIMP-1 and 113-5B7 for MT-MMP-1 (Fuji Chemical Industries, Ltd., Takaoka, Japan).

Immunoprecipitation

Immunoprecipitation was performed as described(1, 11) . 24 h after transfection, COS-1 cells were labeled with 30 µCi/ml [S]methionine (Amersham, SJQ0079, Buckinghamshire, United Kingdom) in methionine-free DMEM and incubated for 5 h at 37 °C. Then, the culture media and the cells were collected. Cells were lysed in lysis buffer (10 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride) and clarified by centrifugation. Both the conditioned media and cell lysates were incubated with monoclonal antibodies (mAbs) against TIMP-1 (50-1H7) or MT-MMP-2 (117-4E1, 117-13B6). Antigen-antibody complexes were precipitated with protein A coupled to Sepharose beads (Pharmacia, Uppsala, Sweden) by centrifugation. After being washed with lysis buffer, the immunoprecipitates were dissolved with sample buffer (50 mM Tris-HCl, pH 6.5, 10% glycerol, 2% SDS, 2% beta-mercaptoethanol, 0.1% bromphenol blue), boiled for 3 min, and separated in 12% SDS-polyacrylamide gel electrophoresis with a discontinuous buffer system. The labeled complexes were visualized with a Bioimage Analyzer BAS1000 (Fuji Photo Film Co., Tokyo).

Indirect Immunofluorescence Staining

The procedure was performed as described(1) . COS-1 cells were cotransfected with expression plasmids on coverslips. After 24 h, the cells were incubated with an mAb against TIMP-1 (5 µg/ml) at 37 °C for 40 min, washed three times with 3% bovine serum albumin/phosphate-buffered saline, and then dried by air and fixed with cold 95% acetone for 5 min. Then, the cells were rehydrated with 3% bovine serum albumin/phosphate-buffered saline and washed with 3% bovine serum albumin/phosphate-buffered saline followed by incubation with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Capel, West Chester, PA) for 30 min at 37 °C. These specimens were finally overlaid with glycerin and observed under an Olympus immunofluorescence microscope(1) .

Activation of Pro-gelatinase A

COS-1 cells were cotransfected with plasmids for gelatinase A and MT-MMP-1, MT-MMP-2 plasmid, or vector plasmid, and HT-1080 cells were cotransfected with MT-MMP-2 plasmid and TIMP-1 plasmid, TIMP-2 plasmid, or vector plasmid, transfected with vector plasmid, and treated with concanavalin A. Cells were then cultured in serum-free DMEM for 24 h. Aliquots of media were mixed with sample buffer and analyzed by gelatin zymography.

Gelatin Zymography

Zymography was performed as described(26) . Samples were mixed with SDS sample buffer in the absence of a reducing agent and incubated for 20 min at 37 °C and separated on a 10% polyacrylamide gel containing 0.1% gelatin. After electrophoresis, gels were soaked in 2.5% Triton X-100 for 1 h and then gelatinolysis was carried out by incubating the gel in 50 mM Tris-HCl (pH 7.6) containing 150 mM NaCl, 10 mM CaCl(2), and 0.02% NaN(3) at 37 °C for 24 h. The gel was stained with 0.1% Coomassie Brilliant Blue R250, and the location of gelatinolytic activity was detected as clear bands in the background of uniform staining.

Northern Blotting

RNA samples (10 µg) extracted from cells were separated by electrophoresis on a denaturing 1.0% agarose gel and transferred onto a nylon membrane Hybond-N (Amersham, Buckinghamshire, UK). Multiple Tissue Northern blot (Clontech) was used for analysis of MT-MMP-2 expression in human tissues. Hybridization and preparation of P-labeled probes were carried out as previously described(8) . Radioactivity was analyzed by a Bioimage Analyzer BAS 1000.


RESULTS

Isolation of a cDNA Encoding a New Member of the MMP Family

As an extension of our previous study to identify new MMP genes expressed in various human tissues, the mRNA sample extracted from an oral malignant melanoma was reverse transcribed and amplified by PCR using oligonucleotide primers designed from the conserved region of MMP genes(2) . Amplified cDNA fragments were subcloned into a plasmid vector and sequenced. Two of the seven cloned fragments were the interstitial collagenase gene and the one for gelatinase B. Two other fragments were identical and showed significant homology to the reported MMP genes (we tentatively called this fragment the MMP-X2 cDNA fragment). The remaining two showed no homology to the MMP genes.

By checking cDNA libraries from various sources by PCR, a human placenta library was found to contain MMP-X2 cDNA fragments and screened to isolate a longer size of the cDNA fragment. We isolated a 2.1-kb cDNA having a long open reading frame that potentially encodes a 604-amino acid protein (Fig. 1).


Figure 1: Nucleotide and the deduced amino acid sequence encoded by MMP-X2 cDNA. The entire nucleotide sequence of the 2.1-kilobase pair MMP-X2 cDNA fragment is presented, and the longest open reading frame that initiates from ATG and terminates at the TGA codon was translated. PRCGVPD, which is the most conserved sequence among the MMP family, is boxed. Zinc binding site is doubleunderlined. The predicted transmembrane domain at the C terminus is underlined, and asterisks indicate hydrophobic amino acids in this domain. The nucleotide sequence data are in the GSDB/DDBJ/EMBL/NCBI nucleotide sequence data base with the accession number D50477.



Sequence Characteristics of the Deduced MMP-X2 Protein

The protein deduced from the MMP-X2 cDNA was aligned well to the reported MMP sequences conserving the characteristic domain structure as a MMP member (Fig. 2). Comparison of the most conserved domain, the catalytic domain, revealed that the homology of MMP-X2 protein is the highest to MT-MMP (66%) (1, 2) and significantly to others, including MMP-12bulletmacrophage elastase (51%)(27) , MMP-2bulletgelatinase A (72-kDa type IV collagenase) (50%)(28) , MMP-9bulletgelatinase B (92-kDa type IV collagenase) (50%)(29) , MMP-1bulletinterstitial collagenase (49%)(30) , MMP-3bulletstromelysin-1 (48%)(31) , MMP-10bulletstromelysin-2 (48%)(32) , MMP-8bulletneutrophil collagenase (47%)(33) , MMP-11bulletstromelysin-3 (46%)(22) , and MMP-7bulletmatrilysin (44%)(32) .



Figure 2: Domain structure of MT-MMP-2. A, alignment of amino acid sequences of the MMP family members. The typical domains are indicated in the figure (signal, propeptide, catalytic, hinge hemopexin-like domains from the N terminus). Specific insertions characteristic to MT-MMPs are indicated by the upwardarrows (IS-1 to IS-3). B, homology between the extra sequences characteristic to MT-MMPs are indicated. Asterisks are the conserved amino acids between the two.



MT-MMP has three characteristic insertions compared to other MMP family members. They are the 11-amino acid insertion (IS-1) between propeptide and catalytic domain, the 8 amino acids (IS-2) in the catalytic domain, and the 75 amino acids (IS-3) at the C terminus, having a TM composed of the 24 hydrophobic amino acids. All such insertions exist in MMP-X2 at the same positions with significant homology (Fig. 2B). In the first insertion, the RXKR sequence, a potential processing site for subtilisin-like enzymes, was conserved(23) . The extra 75 amino acids at the C terminus contain a potential TM domain composed of 24 amino acids with higher hydrophobicity. Thus, MMP-X2 is also expected to be a membrane-type MMP as well. Based on this structural homology to MT-MMP and the localization of the product on the cell surface as demonstrated in the following section, we will call the MMP-X2 gene product MT-MMP-2 and rename the previously identified MT-MMP as MT-MMP-1.

Identification of MT-MMP-2 Product

To identify MT-MMP-2, mAbs against a synthetic peptide unique to MT-MMP-2 (IS-2) were prepared (antibodies 117-4E1 and 117-13B6) and used for immunoprecipitation. COS-1 cells were transiently transfected with MT-MMP-2 expression plasmid and labeled with [S]methionine. Cell lysate and culture medium were prepared and examined by immunoprecipitation using the mAbs (Fig. 3). Both mAbs precipitated a 64-kDa protein specifically from the lysate of cells transfected with the MT-MMP-2 plasmid but not from that of the control. The molecular size of the product was that of the deduced proMT-MMP-2 from the sequence. Three smaller immunoreactive bands (52, 33, and 30 kDa, respectively) were also detected only from the cells transfected with MT-MMP-2 plasmid. None of these proteins were detected in the culture medium. On the other hand, TIMP-1, which was coexpressed as a secretory protein, was detected in the medium as a 28-kDa band and weakly in the cell lysate. Thus, MT-MMP-2 was not a secretory protein like TIMP-1. The result is very similar to that with MT-MMP-1 where MT-MMP-1 is expressed on the cell surface and cannot be released into the culture medium at a detectable level.


Figure 3: Identification of MT-MMP-2 gene product. Immunoprecipitation of MT-MMP-2 is shown. COS-1 cells transfected with MT-MMP-2 plasmid (MT-MMP-2), TIMP-1 plasmid (TIMP-1) or vector plasmid (control) were labeled with [S]methionine for 5 h at 37 °C, and then cell lysates and culture medium were prepared and immunoprecipitated with mAbs against MT-MMP-2 (117-4E1 and 117-13B6) or TIMP-1 (50-1H7). Immunoprecipitates were separated by SDS-polyacrylamide gel electrophoresis, and the radioactivity was detected by autoradiography. MT-MMP-2 protein (64 kDa) and TIMP-1 protein (28 kDa) are indicated by arrows.



Function of the Hydrophobic Stretch at the C Terminus

Similarly to MT-MMP-1, MT-MMP-2 was also immunolocalized on the transfected COS-1 cells (data not shown). Thus, we tried to examine the role of the hydrophobic amino acid stretch of MT-MMP-2 as a TM domain. For this purpose, the TM domain of MT-MMP-2 was fused to a soluble protein TIMP-1 by manipulating the cDNAs in the expression plasmids (TIMP/MT-2). The TM domain of MT-MMP-1 was used as a positive control (TIMP/MT-1). The chimeric proteins were transiently expressed in COS-1 cells by transfection of the plasmids, and localization of the fusion proteins in the culture medium and cell lysate were analyzed by immunoprecipitation using anti-TIMP-1 mAb (Fig. 4A).


Figure 4: Function of the potential transmembrane domain. A, expression of TIMP-1 and its chimeras with the TM domains of MT-MMP-1 or -2 in COS-1 cells. COS-1 cells were transfected with TIMP-1 plasmid (TIMP-1), its chimeras (TIMP-1/MT-1 and TIMP-1/MT-2), or vector plasmid (control). After labeling the cells with [S]methionine for 5 h at 37 °C, the lysates and cultured medium were immunoprecipitated with the mAb against TIMP-1 (50-1H7). TIMP-1 protein and its chimeric proteins were detected as 28- and 32-kDa proteins, respectively. B, immunofluorescence staining. COS-1 cells were transfected with TIMP-1 plasmid (TIMP-1) or TIMP-1/MT-2 plasmid (TIMP-1/MT-2) and incubated with anti-TIMP-1 mAb (50-1H7) prior to fixation. After washing excess mAb, cells were fixed with acetone and stained with fluorescein isothiocyanate-conjugated anti-mouse IgG.



TIMP-1, TIMP/MT-1, and TIMP/MT-2 were expressed as 28-, 32-, and 32-kDa proteins in the cell lysate, respectively. The sizes of the chimeras were as expected from the construct of the fusion genes. TIMP-1 was predominantly detected in the medium, and a small amount was in the cell lysate. However, TIMP/MT-1 was found exclusively in the cell lysate but not in the medium as reported(11) . The localization of TIMP/MT-2 was exactly the same as that of TIMP/MT-1. Thus, the TM domain of MT-MMP-2 has a function similar to that of the MT-MMP-1 in preventing secretion of the fusion protein to the media.

Next, we examined whether the TIMP-1 portion of the chimera is expressed on the cell surface. To show this, transfected cells were incubated with anti-TIMP-1 mAb without fixation, and then indirect immunofluorescence staining was carried out using fluorescein isothiocyanate-conjugated anti-mouse IgG (Fig. 4B). TIMP/MT-2-producing cells were stained as positively as that of TIMP/MT-1, but TIMP-1 producer cells were negative. Thus, we concluded that MT-MMP-2 is the second member of the membrane-type MMP.

Effect of MT-MMP-2 on the Processing of Pro-gelatinase A

Since MT-MMP-2 conserves characteristic structural features of MT-MMP-1, we next examined whether it also induces activation of pro-gelatinase A. COS-1 cells were cotransfected with the expression plasmids for pro-gelatinase A and either MT-MMP-1 or -2. The culture medium was collected and analyzed by gelatin zymography (Fig. 5A). Gelatinase A activity was detected as a 68-kDa band corresponding to a pro-enzyme form when MT-MMPs were not expressed. MT-MMP-1 reportedly induced activation of pro-gelatinase A to the fully activated 62- and 64-kDa intermediate forms(1) . Similar processing was induced by MT-MMP-2. This phenomena was not specific to COS-1 cells because the processing can also be seen by human fibrosarcoma HT1080 cells, which express pro-gelatinase A and B constitutively (Fig. 5B). Activation of pro-gelatinase A by MT-MMP-1 can be more efficiently inhibited by TIMP-2 than TIMP-1 as previously reported(1) . This was also the case on the processing induced by MT-MMP-2.


Figure 5: Activation of pro-gelatinase A by MT-MMP-2 expression. A, activation of pro-gelatinase A in COS-1 cells. COS-1 cells cotransfected with gelatinase A plasmid and MT-MMP-2 plasmid (MT-MMP-2), MT-MMP-1 plasmid (MT-MMP-1), or vector plasmid (control) were cultured in serum-free DMEM for 24 h. Conditioned media were collected and analyzed by gelatin zymography. B, activation of pro-gelatinase A by MT-MMP-2 and effect of TIMPs in HT 1080 cells. MT-MMP-2 plasmid was cotransfected into HT-1080 cells together with TIMP-1 plasmid (lane3), TIMP-2 plasmid (lane4), or vector plasmid (lane2), or vector plasmid alone was transfected (lane1). After transfection, the cells were cultured in serum-free DMEM for 24 h. Aliquots were analyzed as described under ``Materials and Methods.'' The conditioned medium of the cells treated with concanavalin A was also analyzed (lane5).



Tissue Distribution of MT-MMP-2 mRNA

Expression of MT-MMP-2 mRNA in human tissues was analyzed by Northern blotting and compared with that of MT-MMP-1 (Fig. 6A). A band specific to MT-MMP-2 cDNA probe was detected at approximately 12 kb in heart, brain, and placenta tissue samples and was undetectable in the lungs, kidneys, liver, spleen, and muscle. On the other hand, expression of MT-MMP-1 mRNA (4.5 kb) was predominant in the lungs, kidneys, and placenta and was the lowest in the brain. Thus, MT-MMP-2 mRNA showed a different tissue distribution from that of MT-MMP-1, and no cross-hybridization was observed.


Figure 6: Tissue distribution of MT-MMP-2 mRNA. A, RNA blot analysis of MT-MMP-2 mRNA in human tissues. Northern blot (Multiple Tissue Northern, Clontech) was probed with P-labeled cDNA for MT-MMP-2 or MT-MMP-1, and the radioactivity was analyzed by a Bioimage Analyzer BAS 1000. The same membrane was rehybridized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe to confirm the amounts of RNA loaded. B, RNA blot analysis of MT-MMP-2 mRNA in cultured human cell lines. Total RNA (10 µg) extracted from the cells was separated by electrophoresis and transferred to a nylon membrane. This membrane was hybridized and rehybridized as described above. The size of mRNA is 12 kb for MT-MMP-2, 4.5 kb for MT-MMP-1, and 1.8 kb for glyceraldehyde-3-phosphate dehydrogenase.



Expression of MT-MMP-1 and -2 mRNA in various cell lines was also examined (Fig. 6B). MT-MMP-2 mRNA was detected in bladder carcinoma T24 and larynx carcinoma Hep2 cells, where MT-MMP-1 transcripts were detected at low levels. By contrast, MT-MMP-1 transcripts were predominant in squamous cell carcinoma OSC-19 and human embryonal lung fibroblasts where MT-MMP-2 mRNA levels were low. Thus, expression of the genes for MT-MMP-1 and -2 is regulated differently, although they share similar protein structures and functions in activating pro-gelatinase A.


DISCUSSION

In addition to MT-MMP-1 (MT-MMP in the previous paper), which we previously reported(1, 2) , we identified a new MMP gene that was expressed in a human oral malignant melanoma and a human placenta. The isolated 2.1-kilobase pair cDNA contained a sufficient coding frame for MT-MMP-2. However, the transcript in tissues or cell lines was at 12 kb in size. Since the cDNA lacks the typical polyadenylation signal (AATAAA), the 3`-non-coding region of the gene is thought to be missing in the cloned fragment. MT-MMP-1 and -2 are approximately the same in their molecular weights, but they are encoded by 4.5- and 12-kb transcripts, respectively. The most plausible explanation for the difference of the mRNA sizes is the different length of non-coding regions at their 3`-ends.

MT-MMP-2 is the most closely related to MT-MMP-1 in the amino acid sequence (66% homology at the catalytic domain) and in the characteristic insertions compared to other MMPs. These insertions may be important for their function and regulation. For example, the first insertions (IS-1) between the propeptide and catalytic domain contain the conserved RXKR sequences. A similar insertion also exists in stromelysin-3 but not in others (Fig. 2B). These sequences may be the recognition site for processing, since immediately downstream of the RXKR sequences is the reported N terminus of the processed forms of stromelysin 3 and MT-MMP-1(34, 35) . Since RXKR is the consensus sequence for subtilisin-like enzymes, autocatalytic activation mechanism, which is common for other MMPs, may not be applicable for these three MMPs. Indeed, 4-aminophenylmercuric acetate or SDS that induces autocatalytic activation of pro-MMPs cannot activate stromelysin-3 and MT-MMPs.

There exist 8 amino acid insertions (IS-2) in the catalytic domains of MT-MMP-1 and -2 at the same position. Three of the eight amino acids at both ends were conserved. Although the significance of this insertion is not clear, it may modulate substrate specificity of the enzymes from its position in the catalytic domain like the gelatin-binding domain of two gelatinases(36) .

Additional sequences (IS-3) containing the TM domains are found downstream of the hemopexin-like domains of MT-MMPs. Both MT-MMPs are expressed as membrane proteins embedded into the plasma membrane through the TM domains at the C terminus. Thus, these two MMPs form a unique membrane-type subclass in the MMP family, while the others are expressed as a soluble form. We previously aligned the most C-terminal portion of the cysteine residue of MT-MMP-1 to that of the hemopexin-like domain of other MMPs and thought that the TM domain is an insertion in the hemopexin-like domain(1, 2) . However, it is more appropriate that the IS-3 locate downstream of the hemopexin-like domains of MT-MMP-1 and -2 rather than splitting the domain as shown in the alignment in Fig. 2. With this alignment, it becomes possible for MT-MMPs to form a cysteine bridge in the hemopexin-like domain, the conserved structure among the MMPs, outside of the cells.

Expression of MT-MMP-2 in cells, like that of MT-MMP-1, induced activation of the pro-gelatinase A to the fully activated form (62 kDa) through the intermediate form (64 kDa). Thus, both MT-MMPs have similar biochemical activities at least in part, though it remains to be elucidated whether these MT-MMPs have different substrate specificity or not. If both MT-MMPs are similar in function, why are two separate genes required for the organism? The organism may have to utilize these MT-MMPs in different tissue environment or situations. Consistent with this idea, the tissue distribution of the MT-MMP-1 and MT-MMP-2 mRNAs was different in the human tissues. In contrast to MT-MMP-1, which is expressed widely in various tissues, MT-MMP-2 is expressed in only restricted tissues such as brain, heart, and placenta. In particular, brain tissue expresses MT-MMP-2 at the highest level but expresses MT-MMP-1 at the lowest level. The high level expression of MT-MMP-2 in brain may suggest a specific role of the product in the central nervous system. In cell lines, squamous cell carcinoma OSC-19 and human embryonal lung fibroblasts express MT-MMP-1 mRNA at higher levels but MT-MMP-2 mRNA at lower levels. The reverse was also the case; the MT-MMP-1 mRNA level was low in T24 cells where MT-MMP-2 mRNA was expressed predominantly.

Since MT-MMP-2 was originally detected in oral malignant melanoma, whether MT-MMP-2 is also involved in activation of gelatinase A in tumor tissues like MT-MMP-1 is of interest. Our preliminary findings with lung carcinomas where MT-MMP-1 was overexpressed indicated that MT-MMP-2 was not expressed frequently there. (^2)

In addition to the activation of pro-gelatinase A, some of the proteins, such as beta-amyloid precursor protein, tumor necrosis factor-alpha, and V-2 vasopressin receptor, are reported to be processed on the cell membrane by MMP-like activities(37, 38, 39, 40) . MT-MMPs may be responsible for the processing of many biologically important proteins on the cell surface as a regulator. These possibilities remain to be examined.

In this study, we reported MT-MMP-2 as a new member of the MMP family. Since both MT-MMP-1 and -2 have TM domains at the C terminus, we proposed a new subclass for MT-MMPs in the MMP family. Studies of MT-MMPs should provide clues to understand the cell surface events controlling extracellular matrix turnover and diverse biological responses.


FOOTNOTES

*
This work was supported in part by Special Coordination Fund for Promoting Science and Technology from the Ministry of Science and Technology of Japan, by a grant-in-aid for cancer research from the Ministry of Education, Science, and Culture of Japan, and in part by Ciba-Geigy Foundation (Japan) for the Promotion of Science. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by the Fellowships in Cancer Research of the Japan Society for Promotion of Science for Young Scientists.

To whom correspondence should be addressed: Dept. of Molecular Virology and Oncology, Cancer Research Institute, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920, Japan. Tel.: 81-762-34-4504; Fax: 81-762-60-7840; mseiki{at}icews1.ipc.kanazawa-u.ac.jp.

(^1)
The abbreviations used are: MMPs, matrix metalloproteinases; mAb, monoclonal antibody; MT-MMP, membrane-type MMP; PCR, polymerase chain reaction; TIMP, tissue inhibitors of metalloproteinases; TM, transmembrane; DMEM, Dulbecco's modified Eagle's medium; kb, kilobase(s).

(^2)
T. Takino, H. Sato, A. Shinagawa, and M. Seiki, unpublished results.


ACKNOWLEDGEMENTS

We thank Drs. Y. Okada, J. Tanaka, and M. Fujii for critical discussion and Dr. Iwata (Fuji Chemical Industries Ltd.) for cooperation to develop the monoclonal antibodies.

Note added in Proof-Two new MT-MMP-2s were reported at the Gordon Research Conference on Matrix Metalloproteinases (Andover, NH July 16-21, 1995). The one reported by Will et al. (Will, B., and Hinzmann, B.(1995) Eur. J. Biochem. 231, 602-608) was published just prior to this article. Thus, we agreed to rename MT-MMP-2 in this paper as MT-MMP-3.


REFERENCES

  1. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E. & Seiki, M. (1994) Nature 370,61-65
  2. Takino, T., Sato, H., Yamamoto, E. & Seiki, M. (1995) Gene (Amst.) 115,293-298
  3. Woessner, J. F. J. (1991) FASEB J. 5,2145-2154 [Abstract/Free Full Text]
  4. Birkedal-Hansen, H., Moore, W. G., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A. & Engler, J. A. (1993) Crit. Rev. Oral Biol. Med. 4,197-250 [Abstract]
  5. Matrisian, L. M. (1990) Trends Genet. 6,121-125 [CrossRef][Medline] [Order article via Infotrieve]
  6. Liotta, L. A., Steeg, P. S. & Stetler-Stevenson, W. G. (1991) Cell 64,327-336 [Medline] [Order article via Infotrieve]
  7. Matrisian, L. M. (1992) BioEssays 14,455-463 [Medline] [Order article via Infotrieve]
  8. Sato, H., Kida, Y., Mai, M., Endo, Y., Sasaki, T., Tanaka, J. & Seiki, M. (1992) Oncogene 7,77-83 [Medline] [Order article via Infotrieve]
  9. Tsuchiya, Y., Sato, H., Endo, Y., Okada, Y., Mai, M., Sasaki, T. & Seiki, M. (1993) Cancer Res. 53,1397-1402 [Abstract]
  10. Tsuchiya, Y., Endo, Y., Sato, H., Okada, Y., Mai, M., Sasaki, T. & Seiki, M. (1994) Int. J. Cancer 56,46-51 [Medline] [Order article via Infotrieve]
  11. Cao, J., Sato, H., Takino, T. & Seiki, M. (1995) J. Biol. Chem. 270,801-805 [Abstract/Free Full Text]
  12. He, C. S., Wilhelm, S. M., Pentland, A. P., Marmer, B. L., Grant, G. A., Eisen, A. Z. & Goldberg, G. I. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,2632-2636 [Abstract]
  13. Nagase, H., Enghild, J. J., Suzuki, K. & Salvesen, G. (1990) Biochemistry 29,5783-5789 [Medline] [Order article via Infotrieve]
  14. Okada, Y., Morodomi, T., Enghild, J. J., Suzuki, K., Yasui, A., Nakanishi, I., Salvesen, G. & Nagase, H. (1990) Eur. J. Biochem. 194,721-730 [Abstract]
  15. Nagase, H., Suzuki, K., Morodomi, T., Enghild, J. J. & Salvesen, G. (1992) Matrix 1,(suppl.) 237-244 [Medline] [Order article via Infotrieve]
  16. Ward, R. V., Atkinson, S. J., Slocombe, P. M., Docherty, A. J., Reynolds, J. J. & Murphy, G. (1991) Biochim. Biophys. Acta 1079,242-246 [Medline] [Order article via Infotrieve]
  17. Brown, P. D., Levy, A. T., Margulies, I. M., Liotta, L. A. & Stetler-Stevenson, W. G. (1990) Cancer Res. 50,6184-6191 [Abstract]
  18. Azzam, H. S., Arand, G., Lippman, M. E. & Thompson, E. W. (1993) J. Natl. Cancer Inst. 85,1758-1764 [Abstract]
  19. Strongin, A. Y., Marmer, B. L., Grant, G. A. & Goldberg, G. I. (1993) J. Biol. Chem. 268,14033-14039 [Abstract/Free Full Text]
  20. Brown, P. D., Bloxidge, R. E., Anderson, E. & Howell, A. (1993) Clin. Exp. Metastasis 11,183-189 [Medline] [Order article via Infotrieve]
  21. Brown, P. D., Bloxidge, R. E., Stuart, N. S. A., Gatter, K. C. & Carmichael, J. (1993) J. Natl. Cancer Inst. 85,574-578 [Abstract]
  22. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C. & Chambon, P. (1990) Nature 348,699-704 [CrossRef][Medline] [Order article via Infotrieve]
  23. Hosaka, M., Nagahama, M., Kim, W. S., Watanabe, T., Hatsuzawa, K., Ikemizu, J., Murakami, K. & Nakayama, K. (1991) J. Biol. Chem. 266,12127-12130 [Abstract/Free Full Text]
  24. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J. R., Murphy, G. & Reynolds, J. J. (1985) Nature 318,66-69 [Medline] [Order article via Infotrieve]
  25. Sato, H., Kita, M. & Seiki, M. (1993) J. Biol. Chem. 268,23460-23468 [Abstract/Free Full Text]
  26. Hibbs, M. S., Hasty, K. A., Seyer, J. M., Kang, A. H. & Marinardi, C. L. (1985) J. Biol. Chem. 260,2493-2500 [Abstract]
  27. Shapiro, S. D., Kobayashi, D. K. & Ley, T. J. (1993) J. Biol. Chem. 268,23824-23829 [Abstract/Free Full Text]
  28. Collier, I. E., Wilhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E. A. & Goldberg, G. I. (1988) J. Biol. Chem. 263,6579-6587 [Abstract/Free Full Text]
  29. Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A. & Goldberg, G. I. (1989) J. Biol. Chem. 264,17213-17221 [Abstract/Free Full Text]
  30. Goldberg, G. I., Wilhelm, S. M., Kronberger, A., Bauer, E. A., Grant, G. A. & Eisen, A. Z. (1986) J. Biol. Chem. 261,6600-6605 [Abstract/Free Full Text]
  31. Wilhelm, S. M., Collier, I. E., Kronberger, A., Eisen, A. Z., Marmer, B. L., Grant, G. A., Bauer, E. A. & Goldberg, G. I. (1987) Proc. Natl. Acad. Sci. U. S. A. 84,6725-6729 [Abstract]
  32. Muller, D., Quantin, B., Gesnel, M. C., Millon-Collard, R., Abecassis, J. & Breathnach, R. (1988) Biochem. J. 253,187-192 [Medline] [Order article via Infotrieve]
  33. Hasty, K. A., Pourmotabbed, T. F., Goldberg, G. I., Thompson, J. P., Spinella, D. G., Stevens, R. M. & Mainardi, C. L. (1990) J. Biol. Chem. 265,11421-11424 [Abstract/Free Full Text]
  34. Murphy, G., Segain, J. P., O'Shea, M., Cockett, M., Ioannou, C., Lefebvre, O., Chambon, P. & Basset, P. (1993) J Biol Chem. 268,15435-15441 [Abstract/Free Full Text]
  35. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A. & Goldberg, G. I. (1995) J. Biol. Chem. 270,5331-5338 [Abstract/Free Full Text]
  36. Murphy, G., Nguyen, Q., Cockett, M. I., Atkinson, S. J., Allan, J. A., Knight, C. G., Willenbrock, F. & Docherty, A. J. (1994) J. Biol. Chem. 269,6632-6636 [Abstract/Free Full Text]
  37. Miyazaki, K., Hasegawa, M., Funahashi, K. & Umeda, M. (1993) Nature 362,839-841 [CrossRef][Medline] [Order article via Infotrieve]
  38. Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torrance, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S. R., Petersen, M., Gerhart, M., Kozlosky, C. J., March, C. J. & Black, R. A. (1994) Nature 370,218-220 [CrossRef][Medline] [Order article via Infotrieve]
  39. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Well, G., Wood, L. M. & Wooley, K. (1994) Nature 370,555-557 [CrossRef][Medline] [Order article via Infotrieve]
  40. Kojro, E. & Fahrenholz, F. (1995) J. Biol. Chem. 270,6476-6481 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.